Can anything shut down the Gold rally?
CAMBRIDGE, UK - Cambridge Cognition Holdings plc (AIM:COG), a brain health software company, announced several changes to its board and executive leadership team on Thursday.
Rob Baker, who joined the company in 2022 as Head of Product before becoming Chief of Product and Operations, has been appointed to the board as Senior Executive Director while continuing his role as Group Chief Operating Officer.
The company also plans to appoint Alex Livingstone-Learmonth and Ronald Openshaw to the board, pending due diligence checks by its Nominated Adviser. Livingstone-Learmonth, who joined in early 2024 as Chief Commercial Officer, has helped double New Sales Orders in the first half of 2025. Openshaw, who has served as a consultant since 2022, will assume the role of Chief Financial Officer and Head of Corporate Development.
As part of its governance transition, Non-Executive Directors Debra Leeves and Richard Bungay will step down from the board on December 31, 2025, after serving since 2019 and 2020 respectively. Chair Dr. Steven Powell, who has been with the company since 2015 and served as Non-Executive Chair since 2019, will not stand for re-election at the 2026 AGM.
"The board has considered the leadership of the Company carefully since the changes made in September last year," said Dr. Powell in the press release. "We have seen a sustained and meaningful improvement in Company performance in terms of sales and operational achievement."
The leadership changes come as Cambridge Cognition positions itself for its next development phase following the appointment of three new independent Non-Executive Directors since early 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.